Company intelligence / Profile preview

Topelia Aust

Sydney, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

Topelia Therapeutics is an Australian clinical-stage biotechnology company focused on developing small molecule therapies for chronic inflammatory and fibrotic diseases. The company leverages the Nrf2 pathway, a critical cellular defense mechanism against oxidative stress and inflammation, to treat conditions with significant unmet needs. Its lead program, TOP-N5, is an oral Nrf2 activator designed to provide potent anti-inflammatory and antioxidant effects. Topelia is currently advancing TOP-N5 through clinical trials for indications including chronic kidney disease (CKD) and metabolic dysfunction-associated steatohepatitis (MASH).

Therapeutic areas: NephrologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Topelia Aust.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Topelia Aust.

Explore the full profile